In their report of quality-of-life measures in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia before and after a single infusion infusion of tisagenlecleucel in the ELIANA trial, Theodore W Laetsch and colleagues do not mention what proportion of patients received treatment with replacement immunoglobulin infusions as maintenance therapy after tisagenlecleucel. As an anti-CD19 chimeric antigen receptor therapy (CAR-T), treatment with tisagenlecleucel induces B-cell aplasia associated with hypogammaglobulinaemia as a direct pharmacodynamic consequence of its mechanism of action.

中文翻译：

---

CAR T细胞治疗后免疫球蛋白的替代和生活质量。

Theodore W Laetsch及其同事在ELIANA试验中单次输注tisagenlecleucel之前和之后的复发或难治性B细胞急性淋巴细胞性白血病的儿童和年轻人的生活质量测量报告中，没有提及患者在替萨根细核后接受了补充免疫球蛋白输注作为维持治疗。作为抗CD19嵌合抗原受体疗法（CAR-T），使用替萨根细核素治疗可引起与低丙种球蛋白血症相关的B细胞发育不良，这是其作用机理的直接药效学结果。